<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027685</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0927</org_study_id>
    <nct_id>NCT05027685</nct_id>
  </id_info>
  <brief_title>The &quot;Global Paradise System&quot; Registry</brief_title>
  <acronym>GPS Registry</acronym>
  <official_title>The &quot;Global Paradise® System&quot; Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReCor Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry.&#xD;
      In addition to collecting data from patients treated as per standard clinical practice, the&#xD;
      Registry will also regularly collect telemetric Home Blood Pressure (HBP) measurements and&#xD;
      Patient Reported Outcome (PRO) data via a standardized quality of life questionnaire. The&#xD;
      objective of the GPS Registry is to document the long-term safety and effectiveness of the&#xD;
      commercially available Paradise Ultrasound Renal Denervation System when used per its&#xD;
      labelling in patients deemed to be candidates for RDN as per physician's assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
    <description>Rate of mortality attributed to any causality as per site standard practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of new onset end-stage renal disease</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
    <description>eGFR&lt;15 mL/min/m2 or need for renal replacement therapy as per site standard practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Significant decline in renal function</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
    <description>≥50% increase in serum creatinine (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New renal artery stenosis</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
    <description>&gt;70% confirmed by CTA/MRA as per site standard practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of renal artery perforation or dissection requiring an invasive intervention</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major vascular complications (e.g, clinically significant groin hematoma, arteriovenous fistula, pseudoaneurysm) requiring surgical repair, interventional procedure, thrombin injection, or blood transfusion as per site standard practice</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalization for hypertensive crisis or symptomatic hypotension</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalization for major cardiovascular- or hemodynamic-related events (e.g. HF; AF)</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of new onset stroke, TIA or CVA</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute myocardial infarction</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any coronary revascularization</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in average home systolic/diastolic BP in mmHg as compared to enrollment</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in average office systolic/diastolic BP in mmHg as compared to enrollment</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in average ambulatory systolic/diastolic BP in mmHg (daytime, nighttime and 24-hr) as compared to enrollment</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of home systolic BP reductions of ≥5 mmHg, ≥10 mmHg, and ≥15 mmHg</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of office systolic BP reductions of ≥5 mmHg, ≥10 mmHg, and ≥15 mmHg</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ambulatory systolic BP (daytime/24-hr/night-time) reductions of ≥5 mmHg, ≥10 mmHg, and ≥15 mmHg</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who are controlled according to current guidelines</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in office/home/ambulatory pulse pressure in mmHg</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in office/home/ambulatory heart rate in bpm</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects without any anti-hypertensive treatment with analysis stratified by number of enrollment antihypertensive medications</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of quarterly Home BP in mmHg</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from enrollment in quality of life scores as measured by the 12-item Short Form Health Survey (SF-12)</measure>
    <time_frame>Through 5 Years post-procedure</time_frame>
    <description>The 12-item Short Form Health Survey (SF-12) is a measure of health-related quality-of-life. Scores for each domain range from 0 to 100, with a higher score indicating a more favorable health state.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation Treatment</arm_group_label>
    <description>Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Paradise Ultrasound Renal Denervation System</intervention_name>
    <description>The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.</description>
    <arm_group_label>Renal Denervation Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The GPS Registry will collect both retrospective and prospective data in patients treated&#xD;
        as per the sites normal practice with the commercially available Paradise Ultrasound Renal&#xD;
        Denervation System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Appropriately signed and dated informed consent&#xD;
&#xD;
          -  Age ≥18 at time of consent&#xD;
&#xD;
          -  Patient candidate for renal denervation with the Paradise System based on physician's&#xD;
             assessment OR Patient treated with the Paradise Ultrasound Renal Denervation System&#xD;
             within the 6 months prior to consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the contraindications listed in the Instructions for Use will be&#xD;
        excluded.&#xD;
&#xD;
        The contraindications are:&#xD;
&#xD;
          -  Stented renal artery&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Known allergy to contrast medium&#xD;
&#xD;
          -  Renal arteries diameter &lt; 3 mm and &gt; 8 mm&#xD;
&#xD;
          -  Renal artery with Fibromuscular (FMD) disease&#xD;
&#xD;
          -  Renal artery aneurysm&#xD;
&#xD;
          -  Renal artery stenosis of any origin &gt;30%&#xD;
&#xD;
          -  Iliac/femoral artery stenosis precluding insertion of the Paradise catheter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Melvin Lobo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barts NIHR Biomedical Research Centre, William Harvey Research Institute, QMUL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Felix Mahfoud</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKS Universitätsklinikum des Saarlandes, Kardiologie, Angiologie und internistische Intensivmedizin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Reeve-Stoffer, PhD</last_name>
    <phone>+44 (0) 794 774 8006</phone>
    <email>hreeve-stoffer@recormedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lea Doyle</last_name>
    <phone>+1 352 362 1021</phone>
    <email>Lea.Doyle@recormedical.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Renal Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

